Bellevue Group’s BridgeBio Oncology BBOT Stock Holding History

Bellevue Group’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,982	Closed	-$62.5K	–	171
2026 Q1	$62.5K	Buy	+6,982	New	+$75K	﹤0.01%	147

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group's BBOT Position: Q2 2026 in Review

Bellevue Group sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 6,982 shares — an estimated $62.5K sold.

Bellevue Group first reported a position in BBOT in Q1 2026 and held it in 1 quarter. The position peaked at $62.5K in Q1 2026. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Bellevue Group reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
Bellevue Group sold 6,982 BridgeBio Oncology shares in Q2 2026, an estimated $62.5K.
Bellevue Group first reported a position in BridgeBio Oncology in Q1 2026 and held it in 1 quarter.
Bellevue Group's BridgeBio Oncology position peaked at $62.5K in Q1 2026.
65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.